Executive Summary / Key Takeaways
-
Biote Corp. is undergoing a critical transformation after a self-inflicted slowdown: the Q3 2024 launch of its Clinical Decision Support Software (CDSS) distracted the sales force, accelerating practitioner attrition to 8% and halting new clinic growth, turning 2025 into a "transition year" with 8.8% procedure revenue decline.
-
The company's core moat—an integrated practitioner certification platform with vertical integration into pellet manufacturing—remains structurally intact but is being tested by execution missteps and a voluntary recall that cost $1.3 million and threatens near-term margins.
-
Financial performance reveals a tale of two businesses: the high-margin procedure segment (71% of revenue) is shrinking, while dietary supplements (22% of revenue) grew 19% in 2025, though the latter's growth did not fully offset the former's decline.
-
At $1.59 per share, BTMD trades at 2.15x trailing earnings and 4.15x EV/EBITDA, pricing in a pessimistic scenario that assumes continued volume decline and regulatory headwinds, creating potential asymmetry if management's turnaround gains traction.
-
The investment thesis hinges on two variables: whether the expanded sales force (growing from 90 to 120 in 2026) can reverse practitioner attrition and drive new clinic additions, and whether the FDA's scrutiny of compounded hormones spares Biote's 503B facility from disruptive restrictions.
Setting the Scene: The Hormone Optimization Platform Model
Biote Corp., founded in 2012 and headquartered in Irving, Texas, operates a unique practice-building business model in the hormone optimization space that goes far beyond simply selling hormone pellets. The company has built an end-to-end platform that certifies practitioners, provides practice management software, delivers clinical decision support, supplies sterile pellet insertion kits, and offers a proprietary line of dietary supplements. This integrated approach creates multiple touchpoints with over 9,200 Biote-certified practitioners, generating revenue through procedure fees, software subscriptions, and supplement sales.
The company sits at the intersection of powerful demographic trends and a fragmented competitive landscape. The U.S. hormone replacement therapy market exceeds $7 billion and is growing at 7% annually, driven by 20 million men over 45 suffering from hypogonadism and 27 million women experiencing menopause each year. Yet only 28% of menopausal women receive hormone therapy, and just 31% of those receive bioidentical hormones, leaving a massive underserved population. This structural demand tailwind should fuel growth, but Biote's 2025 performance shows the company is currently facing significant internal execution challenges.
Unlike direct-to-consumer telehealth platforms like Hims & Hers Health (HIMS) that bypass practitioners entirely, Biote's B2B model embeds itself within clinical workflows. The company trains physicians, provides inventory management, and offers digital marketing support—creating switching costs that telehealth competitors cannot replicate. However, this practitioner dependency becomes a liability when execution falters, as each lost provider represents not just a revenue stream but a local market presence that competitors can capture.
History with a Purpose: From Growth to Disruption
Biote's evolution explains its current predicament. After establishing its core platform by 2013 with the launch of branded supplements, the company spent a decade expanding its practitioner network, reaching 10 core states that now account for 53% of revenue. The May 2022 Up-C structure provided public currency for acquisitions, enabling the March 2024 purchase of Asteria Health, a 503B outsourcing facility that now supplies over 50% of Biote's pellets. This vertical integration was intended to drive cost savings and supply security; pellet procedure costs fell 19% in 2025.
However, the strategic pivot to launch CDSS in Q3 2024 proved disastrously timed. Management intended the software to "make what we do more mainstream to the average physician" by improving dosing accuracy, but the rollout distracted the sales force at a critical moment. New clinic additions slowed while practitioner attrition accelerated from the historical 5% rate to "high single digits." The problem compounds in an annuity model: each lost practitioner impacts revenue for 12 months, creating a lagging indicator that management cannot quickly reverse.
The May 2025 commercial reorganization—shifting 25% of support roles to field sales and adding new leadership—was the strategic response but created additional disruption. As management admitted, the combination of CDSS distraction and team restructuring created a perfect storm that procedure revenue may not recover from until the second half of 2026.
Technology, Products, and Strategic Differentiation
Biote's core technology is not a single product but a tightly integrated ecosystem. The Biote Method combines practitioner certification, practice management software, inventory systems, and the proprietary CDSS into a unified platform. This creates network effects: as more practitioners join, the collective data improves CDSS algorithms, which enhances patient outcomes and attracts more providers. Management claims to be the only player in the marketplace integrating training, education, and practice building, which contributes to the company's 71.5% gross margins—substantially higher than Progyny (PGNY) at 23.6% or Hims & Hers' implied lower margins.
The CDSS itself represents both opportunity and risk. For new clinics, the software receives "excellent feedback" by simplifying complex dosing decisions, potentially lowering the barrier to entry for average physicians. Yet the deployment process proved so resource-intensive that it slowed new starts. This reveals a critical vulnerability: Biote's high-touch model requires significant sales and support resources, making it difficult to scale rapidly without compromising execution quality.
Vertical integration through Asteria Health provides tangible cost advantages, with pellet procedure costs dropping 19% in 2025. By Q3 2025, Asteria supplied over 50% of pellets. The long-term goal is to make Asteria the primary production facility, securing supply and capturing manufacturing margins. However, the January 2026 voluntary recall—initiated due to potential metal particulate matter—demonstrates the downside of this strategy. The $1.3 million inventory charge is manageable, but the reputational risk to practitioner confidence could be more damaging, especially with attrition already elevated.
The dietary supplement business, while smaller, showcases Biote's ability to monetize its practitioner relationships beyond procedures. Growing 19% in 2025 through e-commerce channels including Amazon (AMZN), supplements generate higher margins and more predictable revenue than procedure-based sales. This diversification provides a growth engine while the core procedure business stabilizes, though at 22% of revenue, it does not yet drive overall growth.
Financial Performance: Evidence of Execution Breakdown
Biote's 2025 financial results show a decline in the core business, partially offset by supplement growth. Total revenue declined 2.5% to $192.22 million, driven by a $13.3 million drop in procedure revenue. The quarterly trajectory worsened throughout the year: Q1 declined 3.6%, Q2 fell 8.4%, Q3 dropped 10.4%, and Q4 plunged 13%. This accelerating decline suggests the CDSS launch and sales reorganization created lasting pressure.
The income statement reflects several non-operational items. Net income rose to $31.6 million, primarily driven by a $13.0 million gain from earnout liability fair value changes and lower legal settlement expenses. Adjusted EBITDA declined 8.2% to $53.5 million, with Q4 EBITDA margin compressing from 30.3% to 25.2%. The gross margin fell from 71.8% to 68% due to the recall charge, but even excluding this, margin expansion from vertical integration was largely absorbed by volume declines.
Cash flow quality also shifted. Operating cash flow dropped $10 million to $35.2 million, with working capital consuming $8.3 million. The change was influenced by a $10 million increase in inventory buildup and a $7.4 million increase in cash used to pay accrued expenses. While the company still generated free cash flow of $30.2 million, the balance sheet shows cash falling from $39.3 million to $24.1 million, partially due to $37.6 million in share repurchase payments.
The segment dynamics reveal a fundamental imbalance. The procedure segment's 8.8% decline reflects both volume and pricing pressure, with management noting increased price competition. Meanwhile, supplement revenue growth of 19% demonstrates the platform's potential, but the absolute dollar increase of $6.9 million only offset about half of the $13.3 million procedure revenue decline.
Outlook, Guidance, and Execution Risk
Management's 2026 guidance reflects the turnaround timeline. Revenue is forecast above $190 million—essentially flat with 2025—while adjusted EBITDA is projected at greater than $38 million, a 29% decline from 2025 levels. This EBITDA drop is attributed to planned investments: expanding the sales force from over 90 to approximately 120 people and investing in the technology platform. The guidance suggests that near-term margin compression is intended to drive future revenue growth.
The procedure revenue outlook remains challenged, with an expected decrease at a "mid to high single-digit percentage rate" in 2026, including recall impact, before a projected return to growth in the second half. Management is monitoring leading indicators like training class attendance, which has accelerated since mid-November 2025. However, the lag between training and revenue generation means any improvement may not materially impact results until late 2026.
Supplement revenue is expected to grow at a "mid to high single-digit rate," a deceleration from 2025's 19% pace. This moderation reflects tougher comparisons after the Amazon onboarding. While supplements provide a stable base, they cannot yet compensate for a shrinking procedure business that represents 71% of revenue.
The recall's financial impact remains a factor. The $1.3 million inventory charge may be followed by additional costs in future periods and potential near-term gross margin pressure if product mix shifts toward third-party manufacturing during the Asteria disruption.
Risks and Asymmetries
The most immediate risk is execution on the sales force expansion. Biote plans to increase sales headcount by 33% in 2026 while implementing a new incentive compensation framework and geographic realignment. If the expanded force cannot convert training attendance into new clinic starts, the 2027 growth trajectory will remain impaired.
Practitioner attrition at 8% represents a threat to the annuity model. In a business where each provider generates recurring procedure revenue, losing nearly one in ten annually requires constant new additions to maintain flat revenue. Management attributes the elevated attrition to the CDSS distraction, but if competitors like Evexias Health Solutions or SottoPelle are gaining share through price competition, attrition could remain above the historical 5% baseline.
Regulatory risk is a significant consideration. The FDA's 2020 NASEM report concluded that compounded bioidentical hormones lack high-quality safety evidence and recommended restricted use. If the FDA implements these recommendations, Biote's business model could face a substantial threat. Furthermore, January 2026 CDSS guidance potentially requires Biote's software to be classified as a medical device needing premarket approval.
The voluntary recall demonstrates how vertical integration concentrates risk. While third-party pellet suppliers spread manufacturing risk across the industry, Biote now concentrates risk in its Asteria facility. Any quality control issue directly impacts the company's reputation and financials.
Competitive Context and Positioning
Biote's competitive position is specialized. Against direct pellet therapy competitors like SottoPelle and Pellecome, Biote's integrated platform and practitioner network provide differentiation, explaining why Biote maintains 71.5% gross margins while others compete primarily on price.
However, indirect competition from telehealth platforms like Hims & Hers represents a fundamental threat. HIMS grew revenue 59% in 2025 to $2.35 billion by offering direct-to-consumer HRT without in-office procedures. While Biote's pellet therapy offers a 3-6 month duration and specific clinical outcomes, HIMS's digital accessibility appeals to a broader patient base. Biote's practitioner-dependent model scales differently than an app-based approach.
Comparing financial metrics reveals Biote's niche efficiency. Biote's 14.1% profit margin and 19.1% ROA exceed HIMS's 5.5% margin and 5.3% ROA. However, HIMS's $4.36 billion market cap reflects investor preference for scale. Progyny shows a different model—employer-sponsored fertility benefits with 23.6% gross margins but 10% growth and a $1.36 billion valuation.
Biote's competitive moat centers on its 9,200 certified practitioners and the Asteria facility. This moat is being challenged by telehealth accessibility and price competition from private pellet suppliers. The recall also places pressure on the quality advantage that supports Biote's pricing.
Valuation Context
At $1.59 per share, Biote trades at a market capitalization of $70.1 million and an enterprise value of $155.9 million. The valuation multiples are 2.15x trailing earnings, 4.15x EV/EBITDA, and 0.36x sales. These multiples reflect a scenario of continued revenue decline and margin compression.
The free cash flow yield of approximately 40% provides a level of protection if the business stabilizes. However, the P/E ratio is influenced by $13.0 million in non-cash earnout gains and cash flow savings from legal settlements. The underlying operational earnings power is lower, though still positive.
Comparing to peers highlights a valuation disconnect. HIMS trades at 37.5x earnings and 1.86x sales, while PGNY trades at 25.5x earnings and 1.06x sales. Even Beauty Health (SKIN) trades at 0.38x sales despite negative margins. The market is pricing in Biote's execution missteps and regulatory overhang.
The balance sheet shows $24.1 million in cash and $45 million in undrawn revolver capacity. While providing liquidity for 2026 investments, the $37.6 million used for share repurchases in 2025 has tightened the cash position.
Conclusion
Biote Corp. stands at a juncture where execution will determine whether 2025's challenges represent a temporary transition or a permanent impairment. The company's integrated ecosystem—certifying providers, supplying pellets through Asteria, and monetizing via supplements—remains a structurally sound approach to the hormone optimization market. However, the CDSS launch and subsequent sales reorganization have exposed operational fragilities.
The investment case hinges on two variables. First, can the expanded sales force convert training momentum into net new practitioner additions that outpace the 8% attrition rate? Second, will the FDA's scrutiny of compounded hormones and CDSS software result in restrictive regulations? The recall's handling will serve as a test case for the company's quality control.
Trading at 2.15x earnings and 4.15x EBITDA, the market has priced Biote for continued decline, creating potential upside if the turnaround succeeds. The 40% free cash flow yield provides a valuation floor, but the stock will likely remain sensitive to practitioner metrics. The next two quarters will reveal whether Biote is a misunderstood platform at its cyclical nadir or a niche leader facing broader industry disruption.
